Dexcel Pharma Technologies Ltd.'s Net Worth

$974 Million

Estimate Recalculated Jul 1, 2024 08:02PM EST

Who is Dexcel Pharma Technologies Ltd.?

Dexcel Pharma Technologies Ltd. has an estimated net worth of $974 Million. This is based on reported shares across multiple companies, which include Roivant Sciences Ltd., Arbutus Biopharma Corp, Myovant Sciences Ltd., Intec Pharma Ltd., Urovant Sciences Ltd., Protalix BioTherapeutics, Inc., and Axovant Gene Therapies Ltd..

SEC CIK

Dexcel Pharma Technologies Ltd.'s CIK is 0001720007

Past Insider Trading and Trends

2019 was Dexcel Pharma Technologies Ltd.'s most active year for acquiring shares with 28 total transactions. Dexcel Pharma Technologies Ltd.'s most active month to acquire stocks was the month of May. 2020 was Dexcel Pharma Technologies Ltd.'s most active year for disposing of shares, totalling 3 transactions. Dexcel Pharma Technologies Ltd.'s most active month to dispose stocks was the month of January. 2018 saw Dexcel Pharma Technologies Ltd. paying a total of $161,399,997.55 for 28,738,300 shares, this is the most they've acquired in one year. In 2021 Dexcel Pharma Technologies Ltd. cashed out on 918,717 shares for a total of $2,088,857.27, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Roivant Sciences Ltd. (ROIV) Snapshot price: $10.33

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+4.05%
4M
$5.00
$20,000,000.00
102.85M
Nov 10
Form 4
+0.04%
40.28K
$3.85
$154,954.16
98.85M
Apr 22 - Apr 25
Form 3
—
0
—
—
0
No matching records found

Urovant Sciences Ltd. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Form 4
+0.04%
18.2K
$8.36
$151,380.99
45.71M
Scheduled
Jun 17 - Jun 19
Form 4
+0.05%
22.01K
$8.12
$177,300.64
45.67M
Scheduled
Jun 12 - Jun 14
Form 4
+0.05%
21.34K
$8.22
$177,247.38
45.62M
Scheduled
Jun 7 - Jun 11
Form 4
+0.05%
21.12K
$7.80
$165,950.15
45.58M
Scheduled
Jun 4 - Jun 6
Form 4
+0.04%
17.75K
$7.86
$138,946.36
45.54M
Scheduled
May 30 - Jun 3
Form 4
+0.03%
14.48K
$7.65
$110,461.18
45.51M
Scheduled
May 24 - May 29
Form 4
+0.02%
9.84K
$7.91
$77,809.93
45.49M
Scheduled
May 22 - May 23
Form 4
+0.04%
9.99K
$8.52
$85,108.42
22.74M
May 21
Form 4
+0.02%
10K
$8.19
$80,524.83
45.45M
May 20
Form 4
+0.03%
11.61K
$7.08
$82,359.46
45.42M
May 16 - May 17
Form 4
+13.38%
2.68M
$14.00
$37,499,994.00
22.7M
Oct 1
Form 3
—
0
—
—
0
No matching records found

Myovant Sciences Ltd. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Form 4
+6.32%
2.42M
$8.25
$19,999,996.50
40.77M
Jun 4
Form 4
+2.98%
1.11M
$20.27
$22,500,004.05
38.34M
Apr 2
Form 3
—
0
—
—
0
No matching records found

Arbutus Biopharma Corp (ABUS) Snapshot price: $2.491

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Form 4
—
0
—
—
0
Jan 12
Form 4
—
0
—
—
0
Oct 16
Form 3
—
0
—
—
0
No matching records found

Axovant Gene Therapies Ltd. (SIOX) Snapshot price: $0.475

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Form 4
+6.71%
6.67M
$1.50
$10,000,000.50
105.95M
Mar 18
Form 4
+11.20%
10M
$1.00
$10,000,000.00
99.29M
Dec 18
Form 4
+19.05%
14.29M
$1.75
$24,999,999.50
89.29M
Jun 5
Form 3
—
0
—
—
0
No matching records found